CureVac NV
5CV
Company Profile
Business description
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Contact
Friedrich-Miescher-Strasse 15
TubingenBW72076
DEUT: +49 707198830
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,088
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,571.40 | 40.30 | -0.47% |
| CAC 40 | 7,825.41 | 85.08 | -1.08% |
| DAX 40 | 23,923.93 | 198.47 | -0.82% |
| Dow JONES (US) | 41,860.44 | 816.80 | -1.91% |
| FTSE 100 | 8,719.60 | 66.86 | -0.76% |
| HKSE | 23,544.31 | 283.47 | -1.19% |
| NASDAQ | 18,872.64 | 270.07 | -1.41% |
| Nikkei 225 | 36,985.87 | 313.11 | -0.84% |
| NZX 50 Index | 12,662.25 | 40.85 | -0.32% |
| S&P 500 | 5,844.61 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,348.70 | 38.10 | -0.45% |
| SSE Composite Index | 3,380.19 | 7.39 | -0.22% |